WAVE Life Sciences Ltd. (WVE) Earns Outperform Rating from Leerink Swann

Leerink Swann restated their outperform rating on shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) in a report published on Wednesday morning, The Fly reports. They currently have a $53.00 target price on the stock, up from their previous target price of $42.00. Leerink Swann also issued estimates for WAVE Life Sciences’ Q4 2018 earnings at ($1.11) EPS, FY2018 earnings at ($4.52) EPS and FY2019 earnings at ($4.34) EPS.

A number of other equities analysts have also weighed in on WVE. Mizuho set a $34.00 price objective on WAVE Life Sciences and gave the stock a buy rating in a research note on Friday, August 18th. Jefferies Group LLC reaffirmed a buy rating and issued a $40.00 price objective (down previously from $42.00) on shares of WAVE Life Sciences in a research note on Thursday, August 10th. BidaskClub raised WAVE Life Sciences from a sell rating to a hold rating in a research note on Saturday, August 26th. Finally, Zacks Investment Research raised WAVE Life Sciences from a sell rating to a hold rating in a research note on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $41.60.

WAVE Life Sciences (WVE) opened at $31.75 on Wednesday. WAVE Life Sciences has a one year low of $15.15 and a one year high of $40.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.50 and a current ratio of 11.50.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.03. The company had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $0.77 million. WAVE Life Sciences had a negative return on equity of 59.52% and a negative net margin of 3,338.68%. equities analysts anticipate that WAVE Life Sciences will post -3.76 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “WAVE Life Sciences Ltd. (WVE) Earns Outperform Rating from Leerink Swann” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://sportsperspectives.com/2017/11/19/wave-life-sciences-ltd-wve-earns-outperform-rating-from-leerink-swann.html.

In other WAVE Life Sciences news, Director Masaharu Tanaka sold 20,747 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $24.21, for a total transaction of $502,284.87. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ra Capital Management, Llc bought 423,398 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were bought at an average cost of $23.34 per share, for a total transaction of $9,882,109.32. The disclosure for this purchase can be found here. Company insiders own 53.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. American International Group Inc. boosted its position in shares of WAVE Life Sciences by 7.1% in the 1st quarter. American International Group Inc. now owns 4,554 shares of the company’s stock worth $125,000 after purchasing an additional 302 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of WAVE Life Sciences by 58.1% in the 2nd quarter. Nationwide Fund Advisors now owns 6,720 shares of the company’s stock worth $125,000 after purchasing an additional 2,470 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of WAVE Life Sciences by 71.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock worth $175,000 after purchasing an additional 3,912 shares in the last quarter. Strs Ohio boosted its position in shares of WAVE Life Sciences by 6.3% in the 2nd quarter. Strs Ohio now owns 11,900 shares of the company’s stock worth $221,000 after purchasing an additional 700 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of WAVE Life Sciences by 62.3% in the 2nd quarter. Rhumbline Advisers now owns 12,502 shares of the company’s stock worth $233,000 after purchasing an additional 4,800 shares in the last quarter. 69.53% of the stock is currently owned by institutional investors and hedge funds.

About WAVE Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

The Fly

Analyst Recommendations for WAVE Life Sciences (NASDAQ:WVE)

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply